Reversal of progressive renal allograft dysfunction with OKT3.
The safety and efficacy of treatment with Orthoclone OKT3 was evaluated in 14 renal transplant patients with allograft dysfunction unresponsive to conventional therapy. Eleven of the 14 initially improved on OKT3, and 9 have retained their kidneys after a median 13-month follow-up. The mean serum creatinine among successes is 2.4 mg/dl. It is concluded that OKT3 is a safe and effective drug for treatment of rejection, and may be used during temporary discontinuation of ciclosporin in cases in which nephrotoxicity is questioned.
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D000954:Antigens, Surface / Q000276:immunology; D017252:CD3 Complex; D003404:Creatinine / Q000097:blood; D005334:Fever / Q000209:etiology; D006084:Graft Rejection; D006801:Humans; D016030:Kidney Transplantation; D013601:T-Lymphocytes / Q000276:immunology
D000911:Antibodies, Monoclonal; D000954:Antigens, Surface; D017252:CD3 Complex; D003404:Creatinine